- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT01112774
Application of Transcranial Direct Current Stimulation (tDCS) in Patients With Chronic Pain After Spinal Cord Injury
Investigation of the Mechanisms of Transcranial Direct Current Stimulation of Motor Cortex for the Treatment of Chronic Pain in Spinal Cord Injury
The purpose of this study is to determine whether the novel treatment of transcranial direct current stimulation (tDCS) could decrease the pain perception of those with spinal cord injury.
We will also determine whether these changes are correlated with the clinical outcome (pain reduction).
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
The active tDCS stimulation sessions will be compared to sham stimulation.
More study details will be provided by Spaulding Rehabilitation Hospital.
Studietyp
Inskrivning (Faktisk)
Fas
- Inte tillämpbar
Kontakter och platser
Studieorter
-
-
Massachusetts
-
Boston, Massachusetts, Förenta staterna, 02115
- Spaulding Rehabilitation Hospital
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
STUDY ELIGIBILITY CRITERIA (similar to the criteria of the Interstitial Cystitis Network)
- Providing informed consent to participate in the study
- 18 to 64 years old
- with traumatic spinal cord injury (complete or incomplete) - for instance, due to fall, car accident or gun shot; (for spinal cord injury only)
- stable chronic pain for at least the three preceding months(for spinal cord injury only)
- score higher or equal to 4cm (0 cm= 'no pain' and 10cm='worst possible pain') on the Visual Analogue Scale (VAS) for pain perception at the baseline/start of the treatment(for spinal cord injury only)
- refractoriness to drugs for pain relieve - such as tricyclic antidepressants, antiepileptic drugs and/or narcotics (pain resistant to at least 2 of these drugs supplied in adequate dosages for six months) (for spinal cord injury only)
- pain is not attributable to other causes, such as peripheral inflammation.
- No clinically significant or unstable medical or psychiatric disorder
- No history of substance abuse
- No neuropsychiatric comorbidity
- No implanted devices for pain control, such as vagal or deep brain stimulators
No contraindications to tDCS:
- metal in the head
- implanted brain medical devices
- No pregnancy
- Eligible to MRI according to MRI screening checklist.
- No use of ventilators
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Dubbel
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: tDCS/Spinal cord injury
Subjects will be randomized to receive 10 sessions of either active or sham tDCS.
Stimulation will be given on consecutive days (Monday- Friday) at 2 mA over the primary motor cortex area.
|
Stimulation will be applied at 2 mA for a total of 20 minutes.
Andra namn:
|
|
Experimentell: tDCS/Healthy subjects
Subjects will receive 2 sessions of stimulation: one active and one sham tDCS on two separate visits.
The order in which they receive the stimulation will be randomized.
Stimulation parameters will be at 2 mA for a total of 20 minutes.
|
Stimulation will be applied at 2 mA for a total of 20 minutes.
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Neurophysiological activity changes after treatment with tDCS
Tidsram: baseline, 2 weeks treatment and follow up (2 weeks)
|
Magnetic resonance spectroscopy (MRS), electroencephalogram (EEG), transcranial magnetic stimulation (TMS)
|
baseline, 2 weeks treatment and follow up (2 weeks)
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Pain changes
Tidsram: Baseline, 2 weeks treatment and follow up (2 weeks)
|
(i) Demographic Data; (ii) Visual analog scale (VAS) for pain; (iii) Analgesic use; (iv) Quality of Life Scale (QOLS); (v) Patient Global Assessment (PGA); (vi) Clinical Global Impression (CGI); (vii) Beck Depression Inventory (BDI); (viii) Visual Analog Scale (VAS) for anxiety; (ix) tDCS Side Effects Questionnaire; (x) Mini-mental status exam; and (xi) Validation of Blinding
|
Baseline, 2 weeks treatment and follow up (2 weeks)
|
Samarbetspartners och utredare
Utredare
- Huvudutredare: Felipe Fregni, PhD, Spaulding Rehabilitation Hospital
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 2010p000190
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .